Yagudina Roza Ismailovna
The aim of the research was a comparative analysis of the economic consequences of smoking in the Russian Federation (from 2009 to 2018). The analysis included calculations direct (costs the cost of economicburden of tobacco-related diseases) and indirect costs (losses gross domestic product (GDP) due to premature disability, premature death, reduced productivity, damage from fires due to smoking). As a result of the study, it was determined that the total economic damage from smoking in 2018 amounted to 5 604 billion rubles, which amounted to about 5.4% of GDP for the year. Compared to 2016, the economic burden of smoking increased by 46% (including inflation).
This article discusses the issues of pharmacoeconomic modeling related to the description of the movement of patients in the pharmacoeconomic model, as well as approaches to determining the course dose of drugs under the condition of integer calculations. In particular, we described two possible ways of distributing patients between treatment regimens in pharmacoeconomic models, also analyzed the effects of simultaneous and uniform entry of patients into the model. As part of the issue of determining the course dose of a drug, we described the limitations and possibilities of calculations based on the active substance and packaging, as well as the transition factor of the remainder of the drug in the next time period.
Type 1 diabetes is an autoimmune disease of the endocrine system, characterized by absolute insulin deficiency. Diabetes control is currently carried out by delivering insulin in a basic bolus insulin therapy regimen by repeated injections of insulin using a syringe pen or continuous subcutaneous infusion of insulin with insulin pumps with the possibility of continuous monitoring of blood glucose levels. The use of insulin pumps is more effective than multiple insulin injections. In order to achieve a high level of quality of life for patients. This article describes the development of insulin pumps in patients with type 1 diabetes.
In order to preserve the health of elderly patients, methodological approach- es to the pharmacoeconomic substantiation of the inclusion of drugs for the treatment of dyslipidemia in the list of vital and essential drugs (EDL) were adapted and an appropriate assessment of the drug of cholesterol absorption inhibition was carried out, which showed that from the point of view of the healthcare system, the presence of this drug in the list will have a positive effect: Impact on the budget by increasing the availability of this drug for patients and delaying the prescription of expensive drugs of the PCSK9 inhibitor class. From a clinical point of view, increasing the availability of cholesterol absorption inhibition drugs for patients when it is included in the list of essential drugs will ensure that the correct sequence of the therapeutic line is followed in the treatment of dyslipidemia.
In recent years, due to the widespread use of pharmacoeconomic modeling for economic and decision analysis, the variety of pharmacoeconomic models has significantly increased, which from the point of view of methodology actualizes the problem of their systematization. The first step in solving this problem is to identify the key principles of a possible classification, for which, in turn, it is necessary to highlight and describe the interaction of the attributes of pharmacoeconomic models. In this article, the authors highlighted, grouped, and described 26 attributes of pharmacoeconomic models.
This article discusses the issues of pharmacoeconomic modeling related to the description of the movement of patients in the pharmacoeconomic model, as well as approaches to determining the course dose of drugs under the condition of integer calculations. In particular, we described two possible ways of distributing patients between treatment regimens in pharmacoeconomic models, also analyzed the effects of simultaneous and uniform entry of patients into the model. As part of the issue of determining the course dose of a drug, we described the limitations and possibilities of calculations based on the active substance and packaging, as well as the transition factor of the remainder of the drug in the next time period.
Type 1 diabetes is an autoimmune disease of the endocrine system, characterized by absolute insulin deficiency. Diabetes control is currently carried out by delivering insulin in a basic bolus insulin therapy regimen by repeated injections of insulin using a syringe pen or continuous subcutaneous infusion of insulin with insulin pumps with the possibility of continuous monitoring of blood glucose levels. The use of insulin pumps is more effective than multiple insulin injections. In order to achieve a high level of quality of life for patients. This article describes the development of insulin pumps in patients with type 1 diabetes.
In order to preserve the health of elderly patients, methodological approach- es to the pharmacoeconomic substantiation of the inclusion of drugs for the treatment of dyslipidemia in the list of vital and essential drugs (EDL) were adapted and an appropriate assessment of the drug of cholesterol absorption inhibition was carried out, which showed that from the point of view of the healthcare system, the presence of this drug in the list will have a positive effect: Impact on the budget by increasing the availability of this drug for patients and delaying the prescription of expensive drugs of the PCSK9 inhibitor class. From a clinical point of view, increasing the availability of cholesterol absorption inhibition drugs for patients when it is included in the list of essential drugs will ensure that the correct sequence of the therapeutic line is followed in the treatment of dyslipidemia.
